This story has been updated from a previous version to include information about BD's ongoing assay-development partnership with Diagenode.

Becton Dickinson's Diagnostics business remains on track to launch a Clostridium difficile assay in the US by the end of this calendar year, its third test for hospital-acquired infections to run on its fully automated BD MAX benchtop molecular testing platform, company executives said recently.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.